Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price increased by Citigroup from $700.00 to $740.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup’s price target indicates a potential downside of 2.77% from the company’s previous close.
A number of other research firms also recently weighed in on REGN. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday. HSBC cut their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $797.75.
Read Our Latest Report on REGN
Regeneron Pharmaceuticals Stock Down 0.2%
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.81 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 2.06 EPS for the current fiscal year.
Insider Buying and Selling at Regeneron Pharmaceuticals
In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
A number of institutional investors have recently modified their holdings of REGN. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $226,000. Arrowstreet Capital Limited Partnership bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $3,183,000. Gabelli Funds LLC grew its position in shares of Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after purchasing an additional 55 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of Regeneron Pharmaceuticals by 18.8% in the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after purchasing an additional 5,120 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.
Key Stories Impacting Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Guggenheim raised its price target to $1,030 from $1,000 and reaffirmed a “Buy” rating, implying substantial upside from recent trading levels. Several other analysts also lifted their targets, to $750, $758, $772 and $795, suggesting some continued confidence in Regeneron’s valuation and outlook. Guggenheim price target report Regeneron analyst price targets
- Neutral Sentiment: Biocon launched Yesafili, a U.S. biosimilar to Regeneron’s Eylea 2 mg. The product competes directly with a key Regeneron ophthalmology treatment and could increase pricing and market-share pressure, although the near-term financial impact remains uncertain. Biocon launches Yesafili biosimilar
- Negative Sentiment: Multiple law firms publicized securities class-action lawsuits against Regeneron and certain executives. The complaints allege that disclosures concerning the Phase III fianlimab-Libtayo trial, including a protocol change and a failed primary endpoint, contradicted earlier positive trial-risk messaging. The firms allege that REGN shares fell substantially after the disclosures and are seeking investors for potential lead-plaintiff roles by September 14, 2026. The allegations have not been adjudicated, but the litigation adds legal, reputational and potential financial risk. Regeneron class action announcement Regeneron investor alert
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
